Dr Raza discusses the current status of aspirin use and the latest clinical trial data.
1. What is the historic importance of aspirin use? (0:12)
2. What are the current practices and guidelines for aspirin use? (1:00)
3. What recent data have been presented in aspirin use? (1:50)
4. What should clinicians do in the future regarding the use of aspirin?(4:42)
5. What is the future of antiplatelet therapy? (5:58)
Speaker’s disclosures: Dr Raza has nothing to disclose in relation to this video interview.
Filmed at the European Association for the Study of Diabetes (EASD) annual meeting, Berlin, Germany, 2018
Share this Video
Related Videos In Cardiovascular Risk
Peter Rossing, EASD 2022: The Relationship Between Cardiovascular and Renal Risks in Diabetes
Diabetes increases the risk of cardiovascular (CV) and renal disease (CVRD). These become major causes of mortality in individuals with diabetes. In this touchENDOCRINOLOGY interview, Prof. Peter Rossing (University of Copenhagen, Copenhagen, Denmark) discusses the relationship between cardiovascular and renal risks in diabetes The abstract entitled: ‘Effect of semaglutide on MACE by baseline kidney function in participants […]
Peter Rossing, EASD 2022: The Effect of Semaglutide on Risk of MACE by Baseline Kidney Function: SUSTAIN 6 and PIONEER 6 Post Hoc Analysis
SUSTAIN 6 and PIONEER 6 investigated the effects of semaglutide versus placebo on major adverse cardiovascular events (MACE). The current post hoc analysis investigated the association between baseline kidney function and risk of MACE, and the effect of semaglutide on risk of MACE by baseline kidney function. In this touchENDOCRINOLOGY interview, Prof. Peter Rossing (University […]
Hertzel Gerstein, ADA 2022: The ELIXA biomarker study, protein biomarkers to identify cardiovascular outcomes in patients with type 2 diabetes and acute coronary syndrome
The ELIXA biomarker study evaluated protein biomarkers as clinical risk factors to identify people with type 2 diabetes and acute coronary syndrome who are at highest risk for cardiovascular (CV) outcomes and death. Professor Hertzel Gerstein (McMaster University, Hamilton, ON, Canada) discusses the outcomes of the ELIXA biomarker study and the implications of the findings […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!